



Rapid chair side test for the detection of  
periodontal pathogens

# PerioPOC and PerioPOC<sup>Pro</sup> at a glance

## COMMON ASSAY FEATURES

- detection of the five most important periodontal pathogens
- chair side results within **20 minutes**
- fast and simple application
- state of the art science

## PerioPOC

- » is our proven **manual** chair side test
- » provides qualitative, visual (blue band) results
- » for low throughput applications

## PerioPOC<sup>Pro</sup>

- » is our **NEW automated** chair side test
- » with software guided **intuitive workflow**
- » provides qualitative **electronic results**
- » for medium to high throughput applications



## FURTHER READING

- Tonetti MS *et al.* Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. J Periodontol. 2018 Jun;89 Suppl 1:S159-S172.
- Polonyi M, *et al.* Assessment of viable periodontal pathogens by reverse transcription quantitative polymerase chain reaction. J Periodontol Res. 2013 Oct;48(5):671-6.
- Socransky SS *et al.* Microbial complexes in subgingival plaque. J Clin Periodontol. 1998 Feb;25(2):134-44

# PerioPOC - clinically relevant results enabled by patented technology

The five most important periodontal pathogens are not only involved in the development and progression of periodontitis, they also contribute to **peri-implantitis** and implant loss.

PerioPOC includes process controls  
PerioPOC provides proven, qualitative results  
PerioPOC exclusively detects living bacteria  
PerioPOC is highly sensitive and specific

Table 1: PerioPOC clinical performance data

|    | Pathogen name                                | LoD (cfu/test)        | Sensitivity (%) | Specificity (%) |
|----|--|-----------------------|-----------------|-----------------|
| Td | <i>Treponema denticola</i>                   | 1.2 x 10 <sup>4</sup> | 91              | 100             |
| Tf | <i>Tannerella forsythia</i>                  | 1.2 x 10 <sup>4</sup> | 86              | 100             |
| Pg | <i>Porphyromonas gingivalis</i>              | 2.5 x 10 <sup>4</sup> | 84              | 100             |
| Pi | <i>Prevotella intermedia</i>                 | 5.3 x 10 <sup>4</sup> | 86              | 100             |
| Aa | <i>Aggregatibacter actinomycetemcomitans</i> | 5.8 x 10 <sup>4</sup> | 100             | 100             |

**PerioPOC** was **clinically** tested in a case-control study involving a total of 125 participants (59 female, 66 male, mean age 52.2 ± 16.9 years). From each patient two sub-gingival plaque samples were taken using the provided paper points (250 samples in total) and analysed with PerioPOC and by a quantitative real-time PCR (qPCR, reference method).

The results show an overall sensitivity of the **PerioPOC** in terms of **clinical findings of 87.82%**. The specificity was 100% for both methods. The detection limits determined using the reference method are summarized in table 1.

The **patented DNA-RNA hybrid technology** of PerioPOC allows a particularly fast, sensitive and specific detection of living bacteria (see study data).


»The perio-diagnostic test is essential for periodontal therapy. The chair side test enables my patients to see and understand the result and the follow-up therapy.«

Dr. G. Bendas, Traunkirchen, AUT

# PerioPOC – road map to success

## RECOGNIZE

Up to 50 % of your patients might be affected by periodontal disease.



Microbial screening can help you to identify periodontitis cases with **greater accuracy** and at **earlier stages**.

## CLASSIFY

The new guidelines for **staging** and **classification** of periodontal and peri-implant diseases recommend to distinguish

- necrotizing periodontitis
- periodontitis in the context of systemic diseases
- chronic and aggressive periodontitis

## TREAT

PerioPOC enables **early intervention** and **monitoring**.

Responsible diagnostic classification leads to personalized therapy for **optimal outcomes**.



PerioPOC enables the careful evaluation of a patient's **response** to standard **treatment** and guides your disease management decisions.

## MAINTAIN

**Bacterial reduction** therapies remain an effective management strategy for many cases to **arrest disease progression**.

**Monitoring** the actual disease progression with new or persisting risk factors are essential tools to modify the patient's **future course** of disease.

# PerioPOC – manual or automated



# PerioPOC product overview


---

| Art. No. | Description               | SU          |
|----------|---------------------------|-------------|
| PPTK001  | PerioPOC® manual test kit | 10 analyses |
| PPHW001  | Mini Dry Bath (heater)    | 1 piece     |

|         |  |             |
|---------|--|-------------|
| PPTK002 | PerioPOC <sup>Pro</sup> automated test kit | 20 analyses |
| PPHW003 | PerioPOCPro starter set w. heater          | 1 set       |
| PPHW004 | PerioPOCPro starter set w./o heater        | 1 set       |

For questions regarding the product and to receive your personal quote, please contact your local distributor.

GENSPEED Biotech GmbH  
Gewerbepark 2  
4261 Rainbach · Austria  
E-mail: [office@genspeed-biotech.com](mailto:office@genspeed-biotech.com)  
Phone.: +43 664 8192991



*Distributor's stamp*